Forus Raises $150M at $3B Valuation, Shifts Telehealth From Video to Workflow

The Center of Gravity Is Moving

Forus raised $150 million at a $3 billion valuation to automate the workflow between prescription and treatment start across doctors, pharmacies, payers, and biopharma. That funding signals a competitive shift: enterprise telehealth procurement is no longer about video visit capacity. It is about reducing friction in prior authorization, reimbursement, and fulfillment at scale.

For buyers, this means budget decisions are migrating from digital front-door teams to cross-functional groups that include IT, pharmacy, revenue cycle, and population health. The winning vendor is the one that shortens time-to-therapy and integrates with payer and pharmacy operations, not the one with the best consumer video interface.

Teladoc Health reinforced this trend by announcing Teladoc One, a cardiometabolic health model that puts 100% of fees at risk and ties payment to outcomes. Select-client launches begin in September 2026, with broader availability in January 2027. That shifts the buying criterion from utilization to measurable total-cost-of-care improvement, raising the bar for vendors that sell transactional visits without risk sharing.

Compliance Is Becoming a Packaged Feature

MD Integrations announced a LegitScript Enterprise Certification Partner arrangement that can begin application reviews in as little as two business days. Karpa Health announced a similar partnership two days later. Both signal that compliance is moving from a separate workstream to a bundled launch accelerator.

For enterprise buyers, this reduces legal review costs, shortens go-live timelines for paid media and payment processing, and lowers dependence on internal compliance teams. It also changes the competitive landscape for white-label telehealth infrastructure vendors, where certification speed is now a differentiation point alongside clinical workflow features.

The practical impact: buyers evaluating telehealth launch platforms should now ask whether compliance support is embedded in the onboarding process or left as a separate procurement decision. Vendors that treat certification as a side project will face longer implementation schedules and higher launch risk.

What This Means for Your Budget

The clearest near-term shift is away from pure telehealth visit volume and toward workflow automation, compliance packaging, and outcome-based contracting. Vendors with proof points around funding strength, certification speed, or fee-at-risk models are gaining an edge in enterprise procurement because they reduce implementation and regulatory uncertainty.

Forus competes directly with workflow-centric platforms like Teladoc, Hims & Hers, and Doximity by targeting the treatment workflow rather than the video visit. Teladoc One competes with population-health vendors that promise ROI without full risk sharing. MD Integrations and Karpa compete with launch-stack providers that leave compliance as a separate process.

The procurement question is no longer "Can this vendor handle video visits at scale?" It is "Can this vendor measurably shorten time-to-therapy, integrate with our payer and pharmacy operations, and reduce our regulatory and performance risk?"

What to Watch

Teladoc One's select-client launches in September 2026 will provide the first real-world test of whether outcome-based contracting can scale in enterprise telehealth. If those pilots succeed, expect buyers to demand similar risk-sharing terms from competitors, which will increase contract complexity and require clear baseline metrics, attribution rules, and governance around cost and clinical outcomes.

Forus's $150 million raise and $3 billion valuation will pressure competitors to demonstrate similar workflow automation capabilities or risk losing procurement cycles to vendors that can show measurable reductions in prior-auth and fulfillment friction. Buyers should ask vendors for specific time-to-therapy benchmarks and integration proof points with payer and pharmacy systems.

Compliance-embedded platforms are becoming table stakes. If your RFP does not include questions about certification support and go-live timelines, you are leaving implementation risk and legal review costs on the table.